CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 501 enrolled
Drug / intervention
Vasopressin, Arginine +2 moredrug
Likely dose
Vasopressin, Arginine 80 IUfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03640949
NCT03640949Phase 3Completed

Vasopressin and Methylprednisolone for In-Hospital Cardiac Arrest - A Randomized, Double-Blind, Placebo-Controlled Trial

Lars Wiuff Andersen·interventional·Posted Aug 21, 2018·Updated Mar 2, 2022

In Brief

A Phase 3 clinical trial evaluating Vasopressin, Arginine, Methylprednisolone, and 1 other intervention for Heart Arrest. Completed, enrolled 501 participants across 10 sites.

Detailed Summary

This is an investigator-initiated, multicenter, randomized, placebo-controlled, parallel group, double-blind, superiority trial of vasopressin and methylprednisolone during adult in-hospital cardiac arrest. There will be ten enrolling sites in Denmark. 492 adult patients with in-hospital cardiac arrest receiving at least one dose of adrenaline will be enrolled. The primary outcome is return of spontaneous circulation and key secondary outcomes include survival at 30 days and survival at 30 days with a favorable neurological outcome.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Arrest
CountriesDenmark

Timeline

Phase 3CompletedFinished
20192020202120222023202420252026
First PostedAug 21, 2018
Enrollment StartSep 17, 2018
Primary CompletionJan 21, 2021
Study CompletionJan 21, 2022
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 7.9 years ago

Interventions

Vasopressin, Argininedrug

20 IE of vasopressin per dose for a maximum of four doses (80 IU)

Methylprednisolonedrug

40 mg methylprednisolone once

NaCldrug

Placebo